In the study by Bojarska-Junak and colleagues [17], a higher median percentage of peripheral blood CD19+ cells with an intracellular APRIL expression and higher level of sAPRIL in plasma of CLL patients has been demonstrated [17]. This evidence concerns the gene TNFSF13 and B-cell chronic lymphocytic leukemia.